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Abnormal degradation of the neuronal
stress-protective transcription factor HSF1
in Huntington’s disease
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Christopher A. Ross7,8,9,10, Cagla Eroglu4,6 & Dennis J. Thiele1,2,5
Huntington’s Disease (HD) is a neurodegenerative disease caused by poly-glutamine
expansion in the Htt protein, resulting in Htt misfolding and cell death. Expression of the
cellular protein folding and pro-survival machinery by heat shock transcription factor 1 (HSF1)
ameliorates biochemical and neurobiological defects caused by protein misfolding. We report
that HSF1 is degraded in cells and mice expressing mutant Htt, in medium spiny neurons
derived from human HD iPSCs and in brain samples from patients with HD. Mutant Htt
increases CK2a0 kinase and Fbxw7 E3 ligase levels, phosphorylating HSF1 and promoting its
proteasomal degradation. An HD mouse model heterozygous for CK2a0 shows increased
HSF1 and chaperone levels, maintenance of striatal excitatory synapses, clearance of Htt
aggregates and preserves body mass compared with HD mice homozygous for CK2a0. These
results reveal a pathway that could be modulated to prevent neuronal dysfunction and muscle
wasting caused by protein misfolding in HD.
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H
untington’s Disease (HD) is a genetically encoded
autosomal dominant neurodegenerative disease caused
by a poly-glutamine (Q) expansion (CAG trinucleotide
repeat) within exon 1 of the Huntingtin (HTT) gene1.
The encoded Htt-polyQ protein is expressed in almost all cells,
which leads to defects in transcription, autophagy, mitochondrial
function, signalling and apoptosis2,3. Although HD preferentially
affects neuronal function and the survival of striatal and cortical
neurons, defects are observed in peripheral tissues in mouse
models and in patients that include skeletal muscle wasting and
cardiac atrophy, perhaps reﬂecting toxicity and apoptosis due to
the ubiquitous expression of Htt-polyQ (ref. 4).
The presence of a pathogenic polyQ expansion causes Htt to
misfold and aggregate, driving inappropriate interactions with
transcription factors, signalling and cell integrity proteins and
other key cellular regulatory factors in both the cytosol and
nucleus5. The protein quality control machinery, including
chaperones, the ubiquitin proteasome, autophagy and other
factors play critical roles in the folding, trafﬁcking, modiﬁcation
and degradation of both newly synthesized and misfolded
proteins in disease6,7. Accordingly, increased expression of
chaperones such as Hsp104, Hsp70, Hsp40 and Hsp27,
or critical components in the autophagy pathway, ameliorates
protein aggregation and cell death in cellular, ﬂy, worm
and mouse polyQ expansion disease models8–11. As chaperones
function in obligate hetero-multimeric complexes, the coordinate
expression of distinct chaperones synergize in the amelioration
of polyQ protein aggregation and cellular stress protection in
polyQ-expansion models12.
Heat shock transcription factor 1 (HSF1) is a stress-responsive
transcription factor that protects cells from protein misfolding,
aggregation and apoptosis13 by expressing genes involved in
protein quality control, stress adaptation and cell survival14.
HSF1 is activated in response to elevated temperature, oxidant
exposure, metals and other conditions that cause protein
misfolding15. Under normal cell growth conditions, HSF1 is
present as an inactive monomer repressed by Hsp40, Hsp70,
Hsp90 and TRiC, protein chaperones involved in the folding
and maturation of hundreds of cellular client proteins16–18. In
response to proteotoxic stress HSF1 assembles as a multimer,
binds heat shock elements in target gene promoters and activates
expression of stress-protective genes19. HSF1 undergoes
many post-translational modiﬁcations including both basal and
stress-induced phosphorylation, sumoylation, ubiquitinylation
and acetylation that mediate repressive or activating regulatory
roles20–22.
Consistent with HSF1 activating protein folding and stress-
protective pathways, hsf1 / mice in the context of an R6/2 HD
model show increased brain Htt aggregation and a shortened
lifespan23, while expression of a constitutively active form of
HSF1 inhibited Htt-polyQ aggregation and prolonged lifespan24.
Moreover, a heterozygous HSF1 mouse model of spinal and
bulbar muscular atrophy with a pathogenic polyQ repeat in
the androgen receptor (AR), exhibited increased AR-polyQ
aggregates in neurons and non-neuronal tissues and enhanced
neurodegeneration25,26.
While there is strong evidence for beneﬁcial effects of HSF1
in polyQ expansion models, HSF1 target gene expression
is compromised in the presence of disease-associated polyQ-
expansion proteins27–30. Pharmacological activation of HSF1
with a blood–brain barrier-penetrant Hsp90 inhibitor increased
HSF1 target gene expression and was initially effective in disease
amelioration28. However, this beneﬁcial effect was observed only
at early stages and was proposed to be due to the inability of
HSF1 to bind target genes in the altered chromatin environment
found in the R6/2 mouse model. Other reports suggest that HSF1
protein levels may affect the expression of the protein folding
machinery components in HD models29,31. Given the therapeutic
potential for HSF1 activation in protein misfolding disease32–34,
it is important to clarify our understanding of the mechanisms by
which HSF1 activation is defective in HD.
Here we demonstrate that HSF1 protein levels are strongly
decreased in HD models, in differentiated human inducible
pluripotent stem cells and in HD patient striatum and
cortex, with a concomitant defect in target gene expression. This
defect is due to inappropriate degradation of HSF1 via
phosphorylation-stimulated ubiquitin-dependent degradation
induced by abnormally high levels of the casein kinase 2a
(CK2a)-prime (CK2a0) kinase and the Fbxw7 E3 ligase.
Diminution of CK2a0 expression in the zQKI175 mouse HD
model restores HSF1 levels and activity and prevents
mutant Htt aggregation, striatal excitatory synapse loss and
cachexia. These studies elucidate a critical molecular mechanism
for inappropriate degradation of the protein misfolding
stress-protective transcription factor HSF1 and suggests a novel
therapeutic target (CK2a0) that is potentially amenable to
pharmacological intervention for the treatment of HD.
Results
Decreased HSF1 correlates with elevated HSF1-P-S303/307. To
explore whether the defect in HSF1 activation lies in changes in
HSF1 abundance in the presence of misfolded polyQ-Htt,
we compared HSF1 protein levels, target promoter occupancy
and gene expression in PC12 cells with Tetracycline inducible
cassettes expressing human Htt exon 1 with non-pathogenic Q
repeats (Htt-Q23-green ﬂuorescent protein (GFP)) versus
pathogenic repeats (Htt-Q74-GFP). We performed these studies
under control (37 C) and heat shock conditions (42 C), allowing
us to both analyse the defect in HSF1 under polyQ protein
expressing conditions and explore the expression of inducible
HSF1 target genes (Fig. 1a). The HSF1 targets Hsp70, Hsp25,
Hspb5 and Bag3 are strongly expressed in response to heat shock
activation in Htt-Q23 cells and in Htt-Q74 cells in the absence of
tetracycline (Dox), while Htt-Q74-expressing cells (þDox)
showed a strong decrease in their expression in response to heat
shock (Fig. 1b; Supplementary Fig. 1A,B). We also analysed
Hsp70 and Hsp25 transcript levels over time after heat shock
in Htt-Q74 cells (Fig. 1c). The decrease in HSF1 target
gene expression in Htt-Q74-expressing cells (Fig. 1b and
Supplementary Fig. 1A) correlated with decreased Hsp70 and
Hsp25 messenger RNA (mRNA) levels (Fig. 1c) and a parallel
reduction in HSF1 occupancy of the Hsp70 promoter (Fig. 1d).
A similar defect in HSF1 activation was observed in response to
azetidine 2-carboxylic acid, a proline analogue that causes protein
misfolding and HSF1 activation (Supplementary Fig. 1C). These
results demonstrate a clear defect in HSF1 DNA binding and
target gene activation under protein misfolding stress conditions
in Htt-Q74 cells, but not Htt-Q23 cells.
A reduction in HSF1 protein levels in Htt-Q74-expressing cells
was observed under control conditions that was exacerbated in
response to proteotoxic heat shock conditions (Fig. 1b). A similar
reduction was observed using whole-cell extracts prepared
with urea or acetone precipitation, ruling out the possibility of
HSF1 partitioning into the insoluble fraction (Supplementary
Fig. 1D,E). However, no signiﬁcant changes in HSF1 mRNA were
observed (Supplementary Fig. 1F). This reduction in HSF1 levels
was accompanied by increased HSF1 phosphorylation at Ser303
and Ser307, located within the central regulatory domain35–37.
Induction of Htt-Q74 expression greatly elevated S303/307
phosphorylation, further enhanced in response to heat shock
(Fig. 1b), and occurred in a time-dependent fashion
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Figure 1 | HSF1 levels are decreased and P-Ser303/307 increased in HD. (a) Diagram of the PC12-HttQ23 and Htt-Q74 proteins and experimental
design. (b) Cells expressing either Htt-Q23 or Htt-Q74 were cultivated at 37 C (c) in the presence of tetracycline (Dox) for 3 days to induce expression,
exposed to heat shock 1 h at 42 C, allowed to recover at 37 C for 7 h (HS) and protein extracts immunoblotted with the indicated antibodies. HSF1 bands
were quantitated using Quantity One image software (BioRad) and values normalized using GAPDH as loading control and referenced to control at 37 C
(c) in the absence of Dox. (c) qRT-PCR analysis of the Hsp70 and Hsp25 genes in Htt-Q74-expressing cells as in B. HS (þDox) group was compared
with HS (Dox) group. Error bars represent means±s.e.m., n¼4. Unpaired t-test, ***Po0.001. (d) Analysis of Hsp70 promoter occupancy by HSF1. Error
bars represent means±s.e.m., n¼ 3. Unpaired t-test, **Po0.01. (e) Mouse-derived striatal STHdhQ7 and STHdhQ111 cells were cultured at 33 C (c), heat
shocked at 42 C 1 h with recovery at 33 C for 7 h and immunoblotted with the indicated antibodies. HSF1 was quantiﬁed using Quantity One image
software and normalized using GAPDH as loading control and referenced to control at 37 C in the non-pathogenic STHdhQ7. (f) Striatal samples fromWild
type (WT) C57BL/6 or KIQ175 mice at 2, 6 and 12 months analysed by immunoblotting (n¼4). (g) Dorsal striatal sections from WT and KIQ175 mice
(n¼ 3) at 6 months assayed by immunohistochemistry (IHC) for mHtt aggregation (1C2), HSF1 and HSF1-S303 phosphorylation using DAPI staining as
control. Scale bar: 10 mm. (h) Gastrocnemius muscle extracts from WTand KI175 mice (n¼4) of the indicated age, immunoblotted for HSF1, Hsp70 and
GAPDH. (i) Protein extracts from HD patient striatum (Supplementary Table 1) and controls immunoblotted with indicated antibodies. (j) HSF1
phosphoproteomic analysis under non-pathogenic (Dox) and pathogenic (þDox) conditions in hsf1 / MEF inducible cell line expressing
GFP-Htt-Q74 expressing HSF1. See Supplementary Fig. 8 for uncropped immunoblots. HSF1 represented by the Regulatory domain, DBD; DNA binding
domain; LZ1-3 and LZ4; leucine zipper domains.
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(Supplementary Fig. 1G). These same changes were observed in
the striatal neuron-derived cells from STHdhQ111/Q111 knock-in
mice when compared with the non-pathogenic STHdhQ7/Q7 cells
(Fig. 1e). A spinal and bulbar muscular atrophy PC12 cell model
(AR-Q112), also showed decreased HSF1 and Hsp25/Hsp70
expression levels and increased HSF1-S303 phosphorylation
compared with non-pathogenic cells (AR-Q10; (Supplementary
Fig. 1H). Together, distinct cellular models of pathogenic
polyQ-expansion protein misfolding disease show defective
HSF1 activation, increased HSF1 S303/307 phosphorylation and
decreased HSF1 protein levels.
To ascertain if these observations made in cellular models of
HD are found in animal models of HD, HSF1 levels were
evaluated in wild-type (WT) C57Bl/6 mice and in the zQ175
(herein KIQ175) heterozygous knock-in HD model. This mouse
model exhibits striatal and cortical excitatory synaptic defects,
abnormal gait and motor defects, loss of body weight, reduced
levels of striatal marker genes and other defects similar to human
HD patients38,39. Although striatal tissue from 2-month-old
KI175 mice showed little difference in the levels of HSF1
compared with wild-type littermates, a strong reduction in HSF1
levels was observed at both 6 and 12 months, as was a reduction
in Hsp70 (Fig. 1f). This correlates with the appearance of
Htt-polyQ aggregates, increased HSF1 S303 phosphorylation in
the striatum (Fig. 1g and Supplementary Fig. 1I) and the age of
onset of motor deﬁcits in this HD model38,39. Similar results were
observed in the cortex and gastrocnemius muscle, where HSF1
and Hsp70 dramatically decreased at 6 and 12 months of age
(Fig. 1h and Supplementary Fig. 1J). Interestingly, Hsp70 levels in
the gastrocnemius muscle of KI175 HD mice also showed a
strong diminution from that found in wild-type mice at 2
months, even before a strong reduction in HSF1 levels (Fig. 1h).
These results demonstrate that HSF1 levels are reduced in striatal
and cortical tissues, and in skeletal muscle in the heterozygous
KI175 HD model, even before the reported onset of motor or
cognitive deﬁcits38,39.
To evaluate HSF1 levels in patients with HD, post-mortem age-
and sex-matched HD and control striatal and cortex samples
were assessed using a total of 14 independent striatal samples and
7 cortex samples (Fig. 1i; Supplementary Fig. 2A–C,F,G and
Supplementary Table 1). In 10 of 14 samples analysed from the
striatum of HD patients, and 5 of 7 samples analysed from the
cortex, a strong reduction in HSF1 levels was evident. Moreover,
HD protein extracts displayed reduced HSF1 electrophoretic
mobility, irrespective of residual protein levels and tissue sample
source, and an increase in HSF1 S303 phosphorylation (Fig. 1i).
Accordingly, the levels of Hsp70 and Hsp25 were decreased in
7 out of 10 HD samples that exhibited decreased HSF1 relative to
controls (Fig. 1i; Supplementary Fig. 2A,B,F), consistent with a
previous transcriptome analyses of human HD brain40.
To explore the role of S303 and S307 phosphorylation in HSF1
regulation in HD, HSF1 phosphoproteomics was performed in
hsf1 / MEFs inducibly expressing human Htt-Q74 or Htt-Q23
and transfected with an HSF1 expression vector (Fig. 1j and
Supplementary Data 1). Out of 95 total serine and threonine
residues present in HSF1, only four were detected as phosphory-
lated in Htt-Q23 cells corresponding to S303, S314, T357 and
S363. In Htt-Q74 cells HSF1 was phosphorylated at S303, S307
and S363, highlighting the increased occurrence of HSF1 S307
phosphorylation under pathogenic polyQ conditions. Although
this analysis does not quantify the abundance of phosphorylation
events, these and other results (Fig. 1b,e,g,i and Supplementary
Fig. 1G) demonstrate that HSF1 S303 and S307 phosphorylation
are speciﬁcally increased in the presence of a pathogenic polyQ
protein in parallel with decreased HSF1 protein abundance and
activity.
Htt-polyQ-dependent HSF1 degradation by the Fbxw7 E3 ligase.
HSF1 protein levels and Hsp70 expression are progressively
reduced when Htt-Q74 is expressed in PC12 cells over the course
of 3 days (Fig. 2a,b), with little difference in the steady-state levels
of HSF1 mRNA (Supplementary Fig. 1F), correlating with
increased HSF1-S303 phosphorylation (Fig. 2a,b). We tested
whether Htt-Q74 expression stimulates HSF1 degradation by
evaluating HSF1 protein levels and activation in the presence of
the proteasome inhibitor MG132, which also results in the
accumulation of misfolded proteins and activation of HSF1. Cells
not expressing Htt-Q74 displayed robust activation of Hsp70 in
the presence of either MG132, or the HSF1 activator 17-AAG,
which inhibits Hsp90 function (Fig. 2c,d). In contrast, the same
cells expressing Htt-Q74 were defective in Hsp70 expression
when treated with 17-AAG and exhibited decreased HSF1 levels
(Fig. 2c). As an indication of HSF1 proteasomal degradation, both
HSF1 levels and activity were preserved by co-incubation with
17-AAG and MG132. Under the latter condition, HSF1 migrated
through SDS–polyacrylamide gel electrophoresis (PAGE) as
multiple species (Fig. 2c), suggestive of one or more HSF1
post-translational modiﬁcations. To test whether Htt-Q74
induces ubiquitin-dependent proteasomal degradation of HSF1,
PC12 cells were transfected with a plasmid expressing HA-tagged
ubiquitin, induced to express Htt-Q74, treated with MG132,
and cell extracts or HSF1 immuno-precipitates immunoblotted
(Fig. 2d,e). Both HSF1 protein levels and the HSF1-S303
phosphorylated species were increased in the presence of
MG132 as a consequence of blocking the proteasome, and
higher molecular weight HSF1-ubiquitylated forms were
observed when Htt-Q74 was expressed in the presence of MG132,
consistent with ubiquitin-proteasome-dependent degradation
(Fig. 2d,e).
The SCF-FBW (Skp1-Cul1-F box) ubiquitin ligase complex
protein Fbxw7 ubiquitinylates HSF1 in cancer cells in a S303/307
phosphorylation-dependent manner41. In melanoma cells Fbxw7
abundance is decreased, resulting in increased HSF1 protein
levels. The analysis of mRNA levels of three E3 ligases (CHIP,
HECTD and Fbxw7) in the striatum of WT and KIQ175 mice
revealed increased Fbxw7 in the KIQ175 mice (Fig. 2f). Increased
Fbxw7 protein levels were observed in STHdhQ111 cells, KIQ175
mice and HD patients (Fig. 2g–i; Supplementary Fig. 2A,B,E)
and correlated with increased HSF1 S303/307 phosphorylation
and low HSF1 protein levels and activity (Figs 1b–f,i and 2e;
Supplementary Fig. 1G). Knocking down Fbxw7 in STHdhQ7 and
STHdhQ111 cells increased HSF1 levels in both cells, with the
increase more pronounced in STHdhQ111 cells, suggesting a role
for this E3 ligase in HSF1 degradation in HD (Fig. 2i).
A previous report showed that the interaction between HSF1
and Fbxw7 is diminished with HSF1 S303A and/or S307A
mutants in cancer cells41. Indeed, co-immunoprecipitation
experiments show that HSF1 S303A mutant interacts less
robustly with Fbxw7 compared to WT HSF1 when expressed in
hsf1 / MEFs (Fig. 2j), recapitulating a role for this
phosphorylation event in the interaction of HSF1 with Fbxw7.
Given that HSF1 S303A exhibited a reduced interaction with
Fbxw7, the effect of the HSF1-S303A mutation on HSF1 stability
was assessed by expressing WT HSF1 or HSF1 S303A in hsf1 /
MEFs expressing Dox-inducible Htt-Q74 (Fig. 2k). As expected,
hsf1 / MEFs expressing Htt-Q74 exhibit decreased HSF1
protein levels and activity and increased S303 phosphorylation,
as compared to un-induced cells. However, the HSF1 S303A
mutation, which precludes phosphorylation at this site, increased
HSF1 protein levels and Hsp70 expression in the presence
of Htt-Q74 protein (Fig. 2k). These results suggest that S303
phosphorylation is critical for Htt-polyQ-dependent degradation
of HSF1 via the action of Fbxw7 and the proteasome.
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Figure 2 | Proteasomal HSF1 degradation in HD is mediated by Phospho-S303/S307. (a,b) PC12 cells expressing Htt-Q74 for 1, 2 or 3 days followed by
Heat Shock (HS) and recovery as indicated. Control and HS in the absence of Dox correspond to cells incubated during 3 days at 37 C. (c) Htt-Q74 cells
Dox-induced or not for 3 days and exposed to 2mM 17-AAG and/or MG132 (5mM) for 6 h and extracts immunoblotted with the indicated antibodies.
(d) Diagram of the effects of 17-AAG and MG132 treatment and Htt-Q74 expression in HSF1. (e) Htt-Q74 cells transfected with human inﬂuenza
haemagglutinin-ubiquitin (HA-Ub) plasmid Dox induced or not and treated with 5mM MG132 treatment for 6 h. Whole-cell extract and HA
immunoprecipitated (IP:HA) and HSF1 immunoprecipitated samples (IP:HSF1) were immunoblotted as indicated. (f) Transcript levels for indicated E3 ligases
evaluated by qRT-PCR from striatum of WT and KIQ175 mice at 6 months. Error bars represent±s.e.m., (n¼ 3). Unpaired t-test, *Po0.05. (g) Human
striatum samples from HD patients and controls and (h) Mouse striatum from 12 months old WTand KIQ175 mice were immunoblotted for HSF1 and Fbxw7.
(i) Fbxw7 siRNA in STHdhQ7 and STHdhQ111 cells using scrambled RNA (Scr) as control. HSF1 was quantiﬁed using Quantity One image software and
normalized using GAPDH as loading control and referenced to control at 37 C in the non-pathogenic STHdhQ7. (j) hsf1 / MEFs transfected with WT HSF1
or S303A mutant and Fbxw7-FLAG; samples immunoprecipitated with anti-FLAG and HSF1 detected. (k) hsf1 / MEFs expressing Dox-inducible Htt-Q74-
GFP transfected with WT HSF1 or HSF1-S303A HS and 1 h recovery at 37 C for 7 h. HSF1 was quantiﬁed using Quantity One image software and normalized
using GAPDH as loading control and referenced to control (Dox) expressing WT HSF1. See Supplementary Fig. 9 for uncropped immunoblots.
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Htt-polyQ-dependent HSF1 phosphorylation by Casein Kinase 2.
To identify protein kinases involved in controlling HSF1
phosphorylation and degradation in HD, we used a previously
developed screen for regulators of human HSF1 expressed in
yeast hsf1D cells (Fig. 3a)42. The basis of the screen is that human
HSF1 (hHSF1) exists in an inactive form in yeast and does not
complement the viability defect of hsf1D cells. Yeast hsf1D cells
harbouring both a galactose-inducible, glucose-repressible yHSF1
plasmid and a constitutively expressed human HSF1 plasmid
were cultured in galactose conditions to allow yHSF-dependent
growth. In glucose medium human HSF1 is insufﬁcient to
promote viability unless small molecules activate HSF1 and
promote cell growth (Fig. 3a). A library of commerical Ser/Thr
and Tyr protein kinase inhibitors was evaluated for molecules
able to support cell viability in a human HSF1-dependent manner
(Fig. 3b). All ﬁve hits from this screen have the common feature
that, among other kinases, they inhibit CK2, a kinase in which the
holoenzyme is composed of 2 regulatory and 2 catalytic
subunits43,44 (Fig. 3c). These results suggested an inhibitory
role for CK2 in human HSF1 regulation in yeast. Because of the
limited speciﬁcity of these kinase inhibitors, the modulation of
human HSF1 by yeast CK2 was tested by deletion of the CKB1
gene, encoding a CK2 stimulatory subunit in S. cerevisiae
(Fig. 3c). When the yeast HSF1 expression plasmid was evicted
from cells expressing human HSF1, isogenic ckb1D cells were
viable and exhibited increased human HSF1 protein levels
compared with WT cells (Fig. 3d–f).
In vitro phosphorylation assays were conducted using puriﬁed
recombinant human glutathione S-transferase (GST)- CK2a or
CK2a0 catalytic subunits, or commercial CK2 holoenzyme, and
recombinant human HSF1 (Fig. 3g). Mass spectrometry analysis
of HSF1 revealed that 11 Ser and 6 Thr residues were
phosphorylated in vitro by CK2 (Fig. 3g and Supplementary
Data 2) with most located in the regulatory domain. Although
some residues were phosphorylated by all three CK2 prepara-
tions, other phosphorylation sites were unique. This is particu-
larly relevant since the catalytic subunits CK2a and CK2a0 can
function in vivo in the absence of the CK2b regulatory subunit43.
Intriguingly, HSF1-S303-P was identiﬁed only in the presence of
CK2 holoenzyme and HSF1-S307-P was identiﬁed solely in the
presence of CK2a0. Of the HSF1 residues phosphorylated in vitro
by CK2, 8 different Ser and Thr residues were mutated to encode
Ala (Supplementary Fig. 3A) but only the HSF1-S303A and/or
S307A mutants promoted robust human HSF1-dependent yeast
growth (Fig. 3h and Supplementary Fig. 3B) consistent with
previous studies of these mutants showing elevated HSF1 protein
levels in yeast32. The HSF1-S303A and S303A/S307A mutants
were further evaluated in the humanized yeast assay in the
presence of the CK2 inhibitor TID43. While TID43
administration allowed WT human HSF1-dependent yeast
growth and potentiated S303A mutant growth, no further
growth stimulation was observed for the S303/307A double
mutant, showing insensitivity to pharmacological CK2 inhibition
(Fig. 3h). Taken together these results demonstrate that CK2
directly phosphorylates human HSF1 at S303 and S307 in vitro
and pharmacological or genetic inhibition of these events
increases human HSF1 activity and abundance in yeast.
To investigate a role for mammalian CK2 (Fig. 4a) in HSF1
degradation in HD, Htt-Q74 expressing cells were incubated with
two CK2 inhibitors that activate human HSF1 in the yeast assay,
TID43 and Emodin (Fig. 3b). Both molecules facilitated Hsp70
expression in non-pathogenic (Htt-Q23) and pathogenic
(Htt-Q74) conditions in a dose-dependent manner (Fig. 4b,c)
and activated HSF1 in human ARPE cells (Supplementary
Fig. 4A,B). Incubation of Htt-Q74 cells with TID43 or Emodin
before or after Htt-Q74 induction (Supplementary Fig. 4C)
decreased HSF1-S303 phosphorylation, increased HSF1 and
Hsp70 levels (Fig. 4d and Supplementary Fig. 4D), decreased
Htt-Q74 aggregates (Fig. 4e,f; Supplementary Fig. 4E) and
increased Hsp70 expression and cell viability in an
HSF1-dependent manner (Fig. 4g and Supplementary
Fig. 4F,G). While Gsk3b phosphorylates HSF1 S303 and drives
HSF1 degradation in cancer cells36,41, a GSK3 inhibitor or GSK3
RNAi knockdown moderately stimulated Hsp70 expression
(Supplementary Fig. 4E,H) and did not impact Htt-Q74
aggregation (Supplementary Fig. 4E). Furthermore, knockdown
of Gsk3a and/or Gsk3b had a detrimental effect on HSF1 protein
stability and did not change the HSF1-S303 phosphorylation state
(Supplementary Fig. 4H).
While yeast CK2 catalytic activity is positively regulated by the
CKB subunits (Fig. 3c), mammalian CK2 activity can be either
activated or inhibited by the CK2b regulatory subunit (Fig. 4a)
thus modulating activity towards speciﬁc substrates43,44.
Consistent with CK2b functioning as a negative regulator of
HSF1 phosphorylation by CK2, silencing of CK2b in the presence
of Htt-Q74 decreased HSF1 protein levels and Hsp70 expression
(Fig. 4h). However, short interfering RNA (siRNA)-mediated
knockdown of the catalytic CK2a0 subunit alone, or in
combination with the CK2a subunit, reduced HSF1 S303 and
S307 phosphorylation (Fig. 4i), increased HSF1 protein levels and
Hsp70 expression and increased cell viability in the presence of
Htt-Q74 (Fig. 4i; Supplementary Fig. 4I–K). A knockdown of
kin-3, the sole C. elegans CK2 catalytic subunit (Supplementary
Fig. 4L), resulted in higher expression of hsp-25 in an
HSF1-dependent manner, suggesting a conservation of function,
but it did not suppress protein aggregation or toxicity in animals
overexpressing polyQ::YFP fusion proteins in body wall muscle
cells, perhaps due to the potent toxicity of the Q37::YFP model
(Supplementary Fig. 4M).
CK2a0 is highly abundant in HD medium spiny neurons. The
abundance of the CK2 catalytic and regulatory subunits was
evaluated in cell and mouse HD models and in striatum from
patients with HD (Fig. 5). In Htt-Q74 expressing PC12 cells
CK2a0 showed increased abundance that was further increased
under HS conditions (Fig. 5a), correlating with increased HSF1
S303/307 phosphorylation and decreased HSF1 levels (Fig. 1b).
In the KIQ175 HD mouse model CK2a0 mRNA (Fig. 5b) and
protein levels were markedly increased in striatum and
gastrocnemius muscle (Fig. 5c,d). Immuno-histochemical analysis
of the dorsal striatum also revealed that CK2a0 expression was
increased in KIQ175 mice (Fig. 5e) while no signal was detected
in CK2a0  / mice (Supplementary Fig. 5A). CK2a0 expression
co-localized with the neuronal marker (NeuN) and the medium
spiny neuron (MSN) markers Darpp32, Ctip2 and Fox1P
(refs 45,46) in both WT and KIQ175 mice (Fig. 5e and
Supplementary Fig. 5B,C). The analysis of the GS and CD68
markers showed no co-localization with astrocytes or reactive
microglia, respectively (Supplementary Fig. 5B,D). These results
demonstrated that MSNs express increased CK2a0 in the presence
of mHtt (Supplementary Fig. 5E). Strikingly, striatal tissue from
patients with HD also exhibited elevated CK2a0 mRNA and
protein levels (Fig. 5f,g). Nine of 14 patients with HD showed
increased CK2a0 expression in the striatum compared with
control samples and among all 10 patients that showed reduced
HSF1, 7 showed increased CK2a0 (Supplementary Fig. 2A,B,D).
HSF1 is degraded in mouse and human MSN-like HD cells.
Our ﬁndings demonstrate a correlation between decreased HSF1
abundance and activity, and increased expression of the HSF1
degradation machinery components CK2a0 and Fbxw7. These
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ﬁndings were corroborated in the striatal-derived mouse HD
STHdhQ111 cell-line compared with STHdhQ7 cells (Fig. 6a).
Importantly, we tested the expression levels of HSF1, Hsp70,
CK2a0 and Fbxw7 in human HD induced pluripotent stem cells
(iPSC)-derived MSNs from 33Q (Control) and 60Q (HD) con-
taining allele individuals in the absence or presence of brain-
derived neurotrophic factor (BDNF; Fig. 6b). Although no dif-
ferences in the expression proﬁle of these proteins were observed
under BDNF-withdrawal stress conditions, we found that HSF1
abundance and Hsp70 expression were reduced, and CK2a0 and
Fbxw7 increased, in the 60Q cell line.
CK2a0 lowering increases HSF1 and decreases mHtt aggregation.
To explore a physiological role for CK2a0 in regulating HSF1
abundance and activity in vivo, the consequences of CK2a0
knock-out was evaluated in otherwise WT mice. CK2a0  / mice
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exhibited higher HSF1 protein levels and Hsp70 expression
compared to CK2a0 þ /þ littermates, suggesting a physiological
role for CK2 in regulating HSF1 abundance and activity
(Supplementary Fig. 6A). Given the dramatic elevation in CK2a0
levels in HD models and patients, mice heterozygous for CK2a0
(CK2a0 þ / ) were generated in the KIQ175 background to
evaluate the impact on HSF1 levels, activity and on the neuro-
pathology observed in this HD model (Fig. 7a and Supplementary
Fig. 6B). KIQ175/CK2a0 þ / mice exhibitedB2.5-fold decreased
CK2a0, and B1.5-fold increased CK2a striatal mRNA levels
compared to KIQ175 littermates (Fig. 7b and Supplementary
Fig. 6C). Heterozygosity of CK2a0 increased expression of the
HSF1 targets Hsp70 and Hsp25 (Fig. 7c and Supplementary
Fig. 6D).
The co-activator peroxisome proliferator-activated receptor
gamma (PGC-1a) is an HSF1 target that is a key regulator of
mitochondrial biogenesis and energy metabolism47. Both PGC-1a
and its target genes, CYCS (cytochrome c), TFAM (mitochondrial
transcription factor) and NDUFS3 (NADH dehydrogenase) are
reduced in the striatum of the N171-82Q HD mouse model and
in human patients, in part underlying the mitochondrial
dysfunction observed in HD (ref. 48). KIQ175/CK2a0 þ / mice
showed elevated expression of PGC-1a and target genes
compared to KIQ175 littermates (Fig. 7d and Supplementary
Fig. 6E). Importantly, HSF1 and Hsp70 protein levels were
increased, mutant Htt aggregates decreased and soluble mutant
and WT Htt protein increased in the striatum of KIQ175/
CK2a0 þ / mice compared to KI175 littermates (Fig. 7e,f;
Supplementary Fig. 6F,G).
CK2a0 reduction preserves MSNs and muscle mass. Previous
studies demonstrated decreased abundance of dendritic spines
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and changes in spine morphology in HD patients and mouse HD
models49. These phenotypes correlate with reduced expression of
vital HSF1 targets in HD, such as Hsp70, which functions in
dendritic maturation and neuronal communication50. Signiﬁcant
alterations in MSN morphology and composition were detected
between WT and KIQ175 mice, with increased immature MSNs
and decreased mature MSNs in KIQ175 mice (Fig. 8a,b). Striatal
degeneration can be detected by alterations in excitatory synapse
formation in KIQ175 mice at an early stage (P21) that may
precede neurodegeneration49. Striatal inputs from the cortex and
thalamus can be distinguished by the differential expression of the
presynaptic proteins VGlut1 (cortico-striatal) and VGlut2
(thalamo-striatal) and their co-localization with post-synaptic
PSD95 (Fig. 8c). CK2a0 heterozygosity increased thalamo-striatal
excitatory synapse number (VGlut2-PSD95 co-localization)
in KIQ175/CK2a0 þ / mice, compared with KIQ175 littermates
at both 5 weeks (Supplementary Fig. 7A,B) and 6 months of age
with no changes in cortico-striatal synapse number, which occurs
only in older KIQ175 mice51 (Fig. 8d–f). Since mature spines are
those actively involved in synapse connectivity, the increase
in mature spine number as a consequence of CK2a0 depletion
(Fig. 8a,b) correlates with increased excitatory synapse
number observed in this background (Fig. 8f). In addition,
KIQ175/CK2a0 þ / mice displayed increased body weight in
comparison to KIQ175 littermates and maintained similar
body mass as wild type littermates beginning at 3 weeks and
extending through at least 6 months (Fig. 8g,h; Supplementary
Fig. 7C).
Discussion
The primary defect in Huntington’s Disease is the expression of a
misfolded and aggregated polyQ-expanded Htt protein5. HSF1
plays a critical role in activating genes encoding proteins that
function in protein quality control, mitochondrial function and
cellular pro-survival factors that ameliorate defects in neuronal
function and survival in HD. Activation of HSF1 either by
over-expression, or by genetic or pharmacological modulation,
is protective in HD models24,28,31–34. Previous studies using an
Hsp90 inhibitor showed only short-term beneﬁts for HSF1
activation that was attributed to global changes in chromatin
structure that precluded HSF1 binding to target promoters28.
However, our data in cellular and mouse HD models and
postmortem HD patient samples, and studies by others in ﬂies
and mice29,31, clearly demonstrate a strong diminution in HSF1
protein abundance.
Moreover, we ﬁnd that the levels of both HSF1, and HSF1
target genes, are strongly reduced in gastrocnemius muscle of the
KIQ175 HD mouse. This is consistent with the accumulation of
nuclear mutant Htt inclusions in muscle ﬁbres52, and perhaps
with the cachexia observed in the periphery in this mouse model
and HD patients53. These studies suggest an intrinsic link
between the periphery and the central nervous system (CNS) in
HD with respect to HSF1 abundance and activity. It has also been
demonstrated that a-synuclein A53T mutant expressing cells, but
not WT a-synuclein cells show HSF1 depletion; similarly, in tissue
of patients with diffuse Lewy body disease HSF1 depletion is
observed54. Rodent models of Alzheimer’s disease also exhibit low
HSF1 levels in the cerebellum55, suggesting that Parkinson’s
disease (PD), Alzheimer’s Disease (AD) and perhaps other
neurodegenerative diseases associated with protein misfolding
may exhibit inappropriate degradation of HSF1.
Here we demonstrate that one mechanism for defective HSF1
activation in HD is pathogenic polyQ-Htt-dependent targeting of
HSF1 for proteasomal degradation, mediated by the action of
CK2 kinase and the phosphorylation of HSF1 at S303/307. Our
observations that CK2a0 catalytic subunit levels are dramatically
elevated in MSNs in rodent HD models, in differentiated human
iPSCs derived from patients with HD and in the striatum from
patients with HD suggest that mutant Htt elevates the expression
or stability of this kinase through as yet unidentiﬁed mechanisms.
Consistent with our ﬁndings, others have shown increased
expression of CK2 in striatal tissue of yeast artiﬁcial chromosome
(YAC) transgenic mice expressing full-length mutant Htt (ref.
56). Moreover, AD models and patients with Alzheimer’s Disease
exhibit low levels of HSF1 and elevated CK2 (refs 55,57,58), and
increasing HSF1 activity in an AD murine model reverses
cerebellar Purkinje cell deﬁciency55. Here, we have demonstrated
that CK2a0 is increased in MSNs in HD, the neuronal sub-type
most susceptible to mHtt aggregation and neurodegeneration,
whereas it is known that CK2a/a0 is increased in the astrocytes in
the hippocampus and temporal cortex of AD patients, the most
affected tissue in AD (ref. 58). Our data demonstrate that CK2a0
and mHtt are found in MSNs in HD mice, while in AD CK2
co-localizes with amyloid deposits in astrocytes. However, it is
currently unclear if this causes the HSF1 protein depletion
that has been reported in AD55,58. Notably, pharmacological
inhibition of CK2 also affects the phosphorylation state of Htt at
Ser13 and Ser16, which alters WT Htt protein aggregation
and localization59. It is currently unknown what the relative
contributions of these or other CK2 targets are to HD phenotype
amelioration when CK2 is inhibited.
HSF1 target genes also encode proteins that function within
the synaptic environment controlling dendritic maturation,
presynaptic signalling pathways and neuronal communication.
Moreover, Hsp70 stabilizes presynaptic proteins such as syntaxin
I, synaptic vesicle protein 2 and synaptotagmin I and attenuates
hypoxia-induced motor and sensory impairment50. HSF1 also
activates BDNF expression, which contributes to the survival of
peripheral and CNS neurons and that is markedly depleted in HD
brain60. Interestingly, amyloid peptide (Ab) transgenic mice
treated with the HSF1 activator 17-AAG had increased BDNF
expression in the hippocampal region and displayed attenuated
Ab-induced synaptic toxicity and memory impairment61. Our
data suggests that reduced expression of HSF1 target genes in the
striatum of HD mice and patients with HD is associated with
decreased levels of HSF1. Prevention of HSF1 degradation by
CK2a0 inhibition increases the expression of chaperones in the
striatum. Indeed, striatal and cortical neurons, which are primary
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Figure 6 | Decreased abundance of HSF1 and increased levels of CK2a0
and Fbxw7 in mouse striatal neurons and differentiated human iPSCs
expressing polyQ-expanded Htt. (a) Mouse STHdh Q7 and Q111 cells were
cultured at 33 C for 48 h. (b) Human iPSC from 33Q (Control) and 60Q
(HD) individuals were differentiated into MSNs for 54 days as previously
described65,66, and transferred to minimal differentiation medium with (þ )
or without ( ) BDNF for 48 h. Protein samples were immunoblotted for
the indicated proteins. See Supplementary Fig. 12 for uncropped
immunoblots.
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sites of neurodegeneration in HD, have reduced levels of Hsp70
expression as compared with other neurons which are more
resistant to mHtt aggregation62. Transcriptomic analysis of brain
from patients with HD revealed reductions in chaperone family
members and other HSF1 target genes with metabolic and
synaptic functions40 (Supplementary Data 3). Although we
demonstrate that HSF1 is responsible for the decrease in
chaperone expression in the striatum, other transcription
factors such as p53 and NF-Y may activate Hsp70 in other
areas of the brain62,63.
The depletion of HSF1 in HD is associated with increased
phosphorylation of S303 and S307 within the HSF1 central
regulatory domain. This region has been previously associated
with negative regulation of HSF1 through poorly understood
mechanisms21,35–37. Nevertheless, R6/2 transgenic mice express-
ing a constitutively active form of HSF1 (lacking a 94 amino-acid
of the central regulatory region encompassing S303 and S307),
inhibited Htt-polyQ aggregate formation and prolonged
lifespan24. Interestingly, in cancer cells phosphorylation of S303
and S307 by distinct protein kinases is required for the interaction
of HSF1 with the Fbxw7 E3 ligase, responsible for ubiquitin-
dependent degradation of nuclear HSF1 in melanoma cancer
cells41. While cancer cells show decreased levels of Fbxw7 and
elevated HSF1 protein levels, pathogenic polyQ-expressing cells
and tissues show the opposite: increased Fbxw7 levels and
increased CK2-dependent S303/307 phosphorylation of HSF1,
which together drives HSF1 degradation (Fig. 9). The importance
of maintaining appropriate levels of HSF1 may provide an avenue
for therapeutic intervention for aging or diseased cells that have a
decreased capacity to maintain protein homeostasis64. However,
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further studies will be required to better understand the
molecular mechanism by which poly-glutamine expanded Htt
drives increased expression of the HSF1 degradation components
CK2a0 and Fbxw7.
Methods
Cell culture and cell lines. Mammalian cell lines used in this study were the
inducible rat PC12 cells expressing HttQ23-GFP and HttQ74-GFP (a gift from
Dr Rubinsztein, University of Cambridge), the inducible rat PC12 cells expressing
AR-Q10 and AR-Q112 (a gift from Dr. Merry, Thomas Jefferson University), the
mouse-derived striatal cells STHdhQ7 and STHdhQ111 (Coriell Cell Repositories),
the hsf1 / mouse embryionic ﬁbroblasts (MEF) cells (from Dr. Benjamin,
Medical College of Wisconsin) and hsf1 / MEFs expressing Htt-Q23-GFP and
Htt-Q74-GFP (prepared in this work), human HEK-293T cells (ATCC CRL-1573)
and human retinal pigment epithelial cell line ARPE-19 (ATCC CRL-2302).
Human HD iPSC-derived from 33Q and 60Q individuals were cultured as pre-
viously described65 and differentiated into MSNs66. On day 42 of differentiation,
cell aggregates were plated into 24-well plates coated with Matrigel (BD). Two
weeks later cells were transferred to neural induction medium to induce MSN
formation.
PC12 cells lines were maintained on Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 5% Tet-approved foetal bovine serum (FBS), 10%
horse serum, 100mgml 1 G418, 75 mgml 1 Hygromycin B and 100Uml 1
penicillin/streptomycin and grown at 37 C. MEFs were maintained in DMEM
supplemented with 10% (FBS), 0.1mM nonessential amino acids, 100Uml 1
penicillin/streptomycin, and 55mM 2-mercaptoethanol and grown at 37 C. Striatal
cells were grown at 33 C in DMEM supplemented with 10% FBS and 100Uml 1
penicillin/streptomycin. HEK-293 T cells were maintained on DMEM
supplemented with 10% (FBS) and 100Uml 1 penicillin/streptomycin grown at
37 C. ARPE cells were grown in DMEM-F12 supplemented with 10% FBS and
100Uml 1 penicillin/streptomycin. Doxycycline induction treatments were
performed using 10mgml 1 for 2–3 days. All culture media were supplemented
with MycoZap-Plus-PR (Lonza) for mycoplasma elimination.
PC12 cells were authenticated by immunoblotting analysis on doxycycline
induction for the presence of Htt-polyQ constructs with anti-GFP antibody,
AR-polyQ cells were authenticated for the presence of AR-polyQ with anti-N20
antibody. The mouse-derived striatal cells STHdhQ7 and STHdhQ111 (Coriell Cell
Repositories) were authenticated by immunoblotting for the presence of mutant
Htt with anti-Htt (Mab2166). The hsf1 / MEF cells were authenticated by
immunoblotting for HSF1 with anti-HSF1 (Enzo 10H8). No misidentiﬁed cells
maintained by ICLAC were used in this study.
Yeast strains and kinase inhibitor analysis. To screen for protein kinase
inhibitors that activate HSF1 in yeast we used the humanized yeast screening assay
described in ref. 42. A battery of 37 different kinase inhibitors was tested. Cells
were incubated in 96-well plates using a range of concentrations (2 nM-20 nM-
0.2 mM-20 mM and 200mM) for each compound using DMSO as solvent negative
control and the small molecule HSF1A as positive control18,42 and OD600 nm was
monitored over 4 days. Experiments were carried out using three independent
biological replicates with three technical replicates for each experiment. Serine
to Alanine mutations were introduced in pRS424-GPD-human HSF1 using
site-directed mutagenesis and vectors transformed into DNY75 yeast strain.
Cells were cultivated in SC-URA-TRP media containing 2% rafﬁnose and 0.01%
galactose. Overnight cultures were serially diluted and plated onto SC-URA-TRP
plates containing Galactose or Dextrose. Plates were incubated for 3 days at 30 C.
TID43 treatments were carried out in ﬂasks in SC-URA-TRP containing 4%
dextrose using 10 mM TID43 or DMSO for 4 days. The CKB1 gene was deleted in
DNY75 using a loxP-KanMX4-loxP deletion cassette and transformed with
pRS423-GPD (HIS) human HSF1. The CKB1 and WT cells were grown in SC-HIS
media overnight and serial dilutions plated onto SC-HIS and 5-FOA plates and
incubated for 3 days at 30 C. Protein extracts were prepared from cells after
overnight growth for HSF1 protein analysis.
Generation of hsf1 / MEF cells expressing Htt-polyQ-GFP. The hsf1 /
MEFs expressing polyQ-Htt-GFP were generated by ampliﬁcation of the Htt exon
1 Q23-GFP and Q74-GFP DNA fragments from PC12 cells by using F1-AscI-GFP
primer 50-ATATGGCGCGCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCG
GGGTGG-30 and R1-MluI-Exon1Htt 50-ATATACGCGTTCACGGCGGGGGCG
GCGGCGGGGGCGGC-30 . HttQ23-GFP and HttQ74-GFP DNA fragments were
cloned into pTRIPz-TeT-ON plasmid (derived from original pTRIPz empty vector
from Thermo Scientiﬁc). pTRIPz empty vector was digested with AgeI and MluI
removing tRFP from the vector and introduced a new multicloning site (MCS)
50-ACCGGTGAATTCGGCGCGCCATCGATCCTGCAGGCTCGAGACGCGT-30
containing an AscI site. AscI and MluI restriction enzyme sites were used to
subclone the Htt-Q23-GFP and Htt-Q74-GFP encoding DNA fragments into the
pTRIPZ-TeT-ON vector. HEK-293 T cells were transfected to produce lentiviral
particules using pTRIPZ-TeT-GFP-HttQ23 or pTRIPZ-TeT-GFP-HttQ74, psPAX2
(packaging vector) and VsgV (envelope vector). Lentiviral particules were used to
infect hsf1 / MEFs and positive clones were selected in 2.5 mgml 1 Puromycin.
Cell transfection and siRNA knockdown experiments. Cells were transfected
using Lipofectamine LTX Reagent (Invitrogen) and following Invitrogen protocol
instructions (Invitrogen protocols 25-0946W) or SE Cell Line Nucleofector Kit.
HttQ74 cells were transfected with HA-Ub vector (Addgene #18712) by using
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Lipofectamine LTX Reagent (Invitrogen) following protocol instructions
(Invitrogen protocols 25-0946W). hsf1 / MEF-GFP-Htt-Q74 cells were
transfected with pcDNA WT HSF1 or the HSF1 S303A mutant plasmid using
Lipofectamine LTX reagent. hsf1 / MEFs were electroporated with FBXW7-
FLAG tag and WT HSF1 or S303A plasmids using the SE Cell Line Nucleofector.
Knockdown experiments were carried out using FlexiTube siRNA (5 nmol)
from Qiagen for the knockdown of HSF1 and CK2 subunits CK2a, CK2a0 , CK2b,
the GSK3 subunits, GSK3a, GSK3b and HttQ74 cells were used with FlexiTube
siRNA (5 nmol) from Qiagen; Rn_Hsf1_4 SI01523144, Rn_Csnk2a1_4
SI02007180, Rn_Csnk2a2_4 SI04730642, Rn_Csnk2b_4 SI01994384, Rn_Gsk3a_4
SI01997016, Rn_Gsk3b_4 SI01519420. For FBXW7 knockdown the mouse-derived
STHdhQ7 and STHdhQ111 cells were used with a combination of 4 siRNAs
(Mm_Fbxw7; SI05586490; SI05586483; SI01001056; SI01001049). As negative
control for silencing experiments, an ON-TARGETplus non-targeting siRNA
(Scrambled) was obtained from Dharmacon. Knockdown experiments in PC12
Htt-Q74 cells were carried out using DharmaFECT1 transfection reagent 24 h
before 10 mgml 1 doxycycline induction for 2 days. Knockdown experiments in
mouse-derived striatal cells were carried out using DharmaFECT1 transfection and
cells were harvested 48 h after transfection.
Viability assays. Cell viability was assessed using the XTT Cell viability assay kit
(Roche) following manufacturer´s recommendations.
RNA preparation and RT-PCR. RNA was extracted from PC12 HttQ74 cells and
human tissue by using RNEasy extraction kit (Qiagen) according to manufacturer´s
instructions. For worm RNA extraction, 50 worms were incubated in a thermo-
cycler at 65 C for 10min and RNA extraction was performed using phenol/
chloroform, precipitated with one volume of 100% isopropanol and 20mg glycogen
and resuspended in water. cDNA for all samples was prepared from 1 mg RNA
using the Supercript First Strand Synthesis System for RT-PCR kit (Invitrogen)
according to manufacturer´s instructions. SYBR green based PCR was performed
with SYBR mix (BioRad).
Chromatin immunoprecipitation. For chromatin immunoprecipitation assays
Htt-Q74 cells were grown in 10 cm plates to 75% conﬂuency, HttQ74 expression
was induced with 10mgml 1 doxycycline for 3 days and heat shocked at 42 C for
30min. Plates were immediately placed on ice and cross-linked with 500ml
Formadehyde for 5min at 4 C. The reaction was terminated by the addition of
Glycine to a ﬁnal concentration of 125mM and incubated on ice for 5min. Cells
were transferred to a 15ml falcon tube and centrifuged at 3,000 r.p.m. for 5min.
Cells were lysed by adding 1ml cell lysis buffer (25mM Tris pH 7.5, 150mM NaCl,
1mM EDTA, 1% Triton X-100, 0.1% SDS) and incubated on ice for 10min. Lysates
were equilibrated in 1ml immunoprecipitation buffer (IPB) (50mM Tris pH 7.5,
150mM NaCl, 1mM EDTA, 1% Triton X-100) and sonicated three times for 30 s.
Samples were centrifuged at 12,000 r.p.m. during 10min. An aliquot (30 ml) was
saved for control input DNA. 5 mg afﬁnity puriﬁed anti-HSF1 antibody (Bethyl)42
was added and samples were incubated overnight at 4 C with constant rocking.
Protein G agarose beads were added and incubated for 4 h at 4 C.
Immunocomplexes were washed, eluted using elution buffer (10mM Tris-HCl, pH
8, 1mM EDTA, pH 8, 1% SDS), and crosslinking was reversed at 65 C for 12 h.
Protein was digested by addition of 5ml Proteinase K and incubated at 37 C for
2 h. Chromatin was puriﬁed using the Qiaquick min-elute PCR puriﬁcation kit
(Qiagen) per the manufacturer’s instructions. SYBR green quantitative PCR was
carried out on pulldown and input samples and the DCt method was used to
determine relative amounts of DNA. Binding of HSF1 was evaluated using
primers spanning the heat shock element of the Hsp70 gene promoter 50-
TGACCTTTCCTGTCCATTCC-30 and 50-CAGATCTGGGGTTAGCTGGA-30
and values were normalized against binding to the actin promoter.
Immunoprecipitation assays. For HSF1 immunoprecipitation cell lysates were
prepared using 500 ml of 1 cell lysis buffer (20mM HEPES, 5mM MgCl2, 1mM
EDTA, 100mM KCl, 0.03% NP-40), incubated on ice 10min and centrifuged at
14,000 r.p.m. for 10min at 4 C. Protein was quantiﬁed by the bicinchoninic acid
assay (BCA) method (Pierce) and all samples were diluted to 1mgml 1. An aliquot
of the cell lysate (25 ml) was mixed with 6 SDS, boiled at 95 C for 5min and
subjected to immunoblot analysis to validate protein levels used for immunopre-
cipitation (referred as whole-cell extract). Samples were pre-cleared with 50 ml
Protein G Dynabeads (Life Technologies) to remove nonspeciﬁc interactions for
5 h at 4 C. Beads were removed using a magnet DYNAL (Invitrogen). Samples
were transferred to a new tube and incubated overnight at 4 C in the presence of
5 ug anti-HSF1 antibody (Bethyl)42 with constant rocking. 50 ml Protein G
Dynabeads (Life Technologies) were added to the samples and incubated for 6 h at
4 C with constant rocking. Beads were washed with 0.1M Na-citrate pH 5.3
during 3 times and pull-down antibody was eluted in 50ml 0.1M Na-citrate pH 2.
Sample was neutralized with 10 ml 1.5M Tris-HCl pH 8.8. Sample was mixed with
6 SDS, boiled at 95 C for 5min and subjected to immunoblotting. For HA-Ub
immunoprecipitation cells lysates were prepared in 500 ml of 1 cell lysis buffer
(5% glycerol, 25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40),
incubated on ice during 10min and centrifuged at 14,000 r.p.m. for 10min at 4 C.
Anti-HA magnetic beads (Thermo Scientiﬁc) were incubated with protein samples
for 1 h at room temperature. Elution was carried out in 0.1M Glycine pH 2.0
and samples were neutralized using 1M Tris pH 8.5. For FBXW7-FLAG tag
immunoprecipitation cell lysates were prepared in 500 ml of 1 cell lysis buffer
(50mM Tris pH 7.4, 10% glycerol, 150mM NaCl, 1mM EDTA, 1% triton X-100),
incubated on ice during 10min and centrifuged at 14,000 rpm for 10min at 4 C.
Anti-FLAG M2 magnetic beads (Sigma) were incubated with protein samples
overnight at 4 C. Elution was carried out in 1 TE, 10% SDS at 65 C for 10min.
Mouse strains. For this study we used a full-length knock-in mouse model of HD
known as zQ175, which harbours a chimeric human/mouse exon 1 carrying an
expansion of B175 CAG repeats and the human poly-proline region38, at 2, 6
and 12 months of age comparing to WT (C57BL/6) animals at the same age.
Two females and two males were use for each genotype and age. Breeding and
genotyping conditions are detailed in Supplemental Experimental Procedures.
For analysis on the effect of the absence of CK2a0 in the HSF1 protein abundance
we obtained CK2a0 heterozygous mice (CK2a0(þ / )) males and females from
Dr Seldin. For our analyses on the effect of the absence of CK2a0 in the
KIQ175 background (C57BL/6) we crossed males CK2a0(þ / ) and females
Htt(zQ175/þ ) generating the four genotypes; WT (CK2a0(þ /þ ) Htt(þ /þ )),
CK2a0(þ / ) (CK2a0(þ / ) Htt(þ /þ )), KIQ175 (CK2a0(þ /þ ) Htt(zQ175/þ )),
KIQ175/CK2a0(þ / ) (CK2a0(þ / ) Htt(zQ175/þ )). Animals were analysed at
5 weeks and 6 months of age. Sample size was set to a minimum of three animals
per genotype for every analysis. For body weight monitoring only males were
evaluated. No randomization of animals was used in this study. The IACUC of
Center of Animal Care and Use at Duke University approved the animal protocol
used in this project (approval number: A173-14-07).
Immunohistochemistry. Mice were perfused intra-cardially with tris-buffered
saline (TBS) (25mM Tris-base, 135mM Nacl, 3mM KCl, pH 7.6) supplemented
with 7.5 mM heparin followed with 4% PFA in TBS as previously described in ref.
49. Brains were dissected, ﬁxed with 4% PFA in TBS at 4 C overnight,
cryoprotected with 30% sucrose in TBS overnight and embedded in a 2:1 mixture
of 30% sucrose in TBS:OCT (Tissue-Tek). Brains were cryo-sectioned at 20mm
using a Leica CM3050S, washed and permeabilized in TBS with 0.2% Triton X-100
(TBST). Sections were blocked in 5% normal goat serum (NGS) in TBST for 1 h at
room temperature. Primary antibodies were diluted in 5% NGS in TBST: mouse
anti-1C2 (mHtt) 1:500 (Millipore), rat anti-HSF1 1:500 (Enzo SPA-950-F), rabbit
anti-HSF1-S303-P 1:1,000 (Ab47369), rabbit anti- CK2a0 (EAP0505) (Elabscience)
1:200, rat anti-Darpp32 (R&D Systems) 1:1,000, mouse anti-Glutamine Synthetase
(BD Biosciences 610517) 1:1,000, rat anti-CD68 (clone FA-11) (BioLegend 137002)
1:1,000, mouse anti-NeuN (clone A60) (Millipore MAB377) 1:1,000, mouse
anti-Fox1P (JC12) (Abcam) 1:500, rat anti-Ctip2 (Abcam) 1:500. Sections were
incubated overnight at 4 C with primary antibodies. Secondary Alexa-ﬂuorophore-
conjugated antibodies (Invitrogen) were added (1:200 in TBST with 5% NGS)
for 2 h at room temperature. Slides were mounted in Vectashield with DAPI
(Vector laboratories), and images acquired on a confocal laser-scanning
microscope (Leica SP5).
Synapse quantiﬁcation in mouse brain sections. Three independent coronal
brain sections were used for each mouse, containing the dorsal striatum (bregma
0.5–1.1mm) and were stained with presynaptic VGlut1 or VGlut2 (Chemicon,
anti-guinea pig, 1:500) and postsynaptic PSD95 (Zymed, Rabbit, 1:500) markers as
described previously49. Secondary antibodies used were goat anti-guinea pig Alexa
488 (VGlut1/2) dilution 1:200 and goat anti-rabbit Alex 594 (PSD95) dilution 1:200
(Invitrogen). Three mice for each genotype; WT, CK2a0(þ / ), KIQ175 and
KIQ175/CK2a0(þ / ) were evaluated in a double-blinded fashion. The 5mm-thick
confocal scans (optical section depth 0.33 mm, 15 sections per scan, imaged area per
scan¼ 20.945 mm2) of the synaptic zone in dorsal striatum were performed at 63
magniﬁcation on a Leica SP5 confocal laser-scanning microscope. Maximum
projections of three consecutive optical sections (corresponding to 1 mm depth)
were generated. The Puncta Analyzer Plugin for ImageJ (available upon request;
c.eroglu@cellbio.duke.edu) was used to enumerate co-localized synaptic puncta.
This assay takes the advantage of the fact that presynaptic and postsynaptic
proteins reside in separate cell compartments (axons and dendrites, respectively),
and they would appear to co-localize at synapses because of their close proximity.
The number of animals used in our study was 12 mice for each genotype group and
sex. At least 5 optical sections per brain section and at least 3 brains sections per
animal were analysed, making a total of 45–60 image data sets per brain region in
each genotype/age.
Golgi Cox staining and dendritic spine analysis. Golgi Cox staining was
performed on WT, CK2a0(þ / ), KIQ175 and KIQ175/CK2a0(þ / ) mice
(three mice per genotype) using FD Rapid GolgiStain Kit (FD NeuroTechnologies).
Dye-impregnated brains were embedded in Tissue Freezing Medium (TFM, TBS),
rapidly frozen on ethanol pretreated with dry ice, cryo-sectioned coronally at
200 mm thickness and mounted on gelatin-coated microscope slides (Southern
Biotech). Sections were stained according to directions provided by the
manufacturer. Sections that contain the dorsal striatum were imaged and MSNs in
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the striatum were identiﬁed by their morphology. Secondary and tertiary apical
dendrites were imaged for spine analysis as follows: z-stacks (30mm total on z-axis,
single section thickness¼ 0.5 mm) of Golgi-stained dendrites were taken at 63
magniﬁcation on a Zeiss AxioImager M1 microscope. A series of TIFF ﬁles
corresponding to each image stack were loaded into the Reconstruct programme
(http://synapses.clm.utexas.edu) and spine analyses performed as previously
described49,67. The clasiﬁcation of spines is based on width, length, and
length:width ratio measurements taken using the Reconstruct software
(http:// synapses.clm.utexas.edu; RRID:nif-0000-23420) designed and validated67.
Spines were identiﬁed and classiﬁed by choosing 10 mm segments of dendrites and
identiﬁed on selected dendritic stretches. The z-length (spine length) and spine
head width were measured for each spine. Measurements were exported to a
custom Microsoft Excel macro that was used to classify spines based on the width,
length, and length:width ratio measurements taken in Reconstruct. Spines were
categorized based on the following hierarchical criteria: (1) more than one spine
head¼ ‘branched spine,’ (2) head width40.7 mm¼ ‘mushroom spine,’
(3) length42 mm¼ ‘ﬁlopodia,’ (4) length:width 41¼ ‘thin spine,’ and
(5) length:width r1¼ ‘stubby spine.’ Branched and mushroom spines were
identiﬁed as mature spines, thin and stubby spines were categorized as
intermediate spines, and ﬁlopodia were classiﬁed as immature spines. Statistical
analyses of changes in spine density, length, width and spine type were conducted
in the Statistica programme (StatSoft): A total of 3 animals per genotype, 15
dendrites per animal, 45 dendrites per genotype were analysed in MSNs in the
dorsal striatum in a blinded fashion. The number of spines analysed per neuron
type per age per genotype exceeded 1,000.
Human samples. HD Brain tissues were obtained from three independent sources;
from Banc de Teixits Neurologics Biobanc Hospital Clinic-IDIBAPS (Barcelona
Brain Bank) via Dr Isidre Ferrer68 following the guidelines of the local ethics
committees; from Duke Kathleen Price Bryan Brain Bank and from Harvard Brain
Tissue Resource Center. Cases with and without clinical neurological disease were
processed in the same way following the same sampling protocols. Control and HD
cases were compared pairwise for sex, age and postmortem time (Supplementary
Table 1). Brain tissue was homogenized in 25mM Tris-HCl pH 7.4, 150mM NaCl,
1mM EDTA, 0.1% SDS, 1% Triton X-100. Extra SDS was added to the suspension
to a ﬁnal concentration of 2% (w per v) and heated at 95 C for 5min. The
homogenate was sonicated 3 times 45 s on ice, centrifuged at 12,000 r.p.m. for
10min and protein concentration determined using the BCA protein quantiﬁcation
assay (Pierce). A total of 60 mg protein was loaded onto SDS–PAGE for
immunoblotting.
mHtt expression and aggregation analysis. Protein samples from mouse stria-
tum at 6 months were prepared in cell lysis buffer (25mM Tris pH 7.4, 150mM
NaCl, 1mM EDTA, 1% Triton-X100 and 0.1% SDS). Extra SDS was added to the
suspension to a ﬁnal concentration of 2% (w per v) and lysates heated at 95 C for
5min to solubilize tissue. Total tissue homogenate was then sonicated three times
45 s on ice and centrifuged at 12,000 r.p.m. for 10min. Samples were subjected to
immunoblotting using a 7.5% stain-free criterion gel and transferred into PDVF
membrane under semi-dry conditions for 1 h at 15V. WT and mutant Htt
expression and Htt aggregates were visualized using the Anti-Htt antibody
Mab2166 (Millipore). Analysis of Htt-Q74 aggregation in the presence of TID43
kinase inhibitor in PC12 cells was assessed by ﬂuorescence microscopy. Htt-Q74-
GFP expressing cells were seeded into a 6-well plate and treated with either DMSO
or 1 mM TID43 for 6 h before 10 mgml 1 doxycycline followed by a 48 h incu-
bation. Cells were heat shocked for 1 h at 42 C. Fluorescence was analysed using a
Zeiss Axio Observer Fluorescence microscope. For quantiﬁcation of ﬂuorescence
microscopy, B500 cells were counted for each treatment. The number of cells
containing aggregates was calculated as a percentage of the total number of cell
counted. Analysis of Htt aggregation in the Htt-Q74 cell line was analysed by
immunoblotting. Cells were seeded (5 105 cells per well) into a 6-well plate and
treated with DMSO, SB21 or TID43 (1mM) for 6 h before 10mgml 1 doxycycline
induction for 3 days. Cells were heat shocked for 1 h at 42 C followed by 6 h
recovery at 37 C. Extracts were prepared in cell lysis buffer (25mM Tris pH 7.4,
150mM NaCl, 1mM EDTA, 1% Triton-X100 and 0.1% SDS), and soluble and
insoluble fractions were separated by centrifugation and analysed by immuno-
blotting using GFP antibody as marker for Htt-Q74-GFP presence in the pellet
fraction. A ﬁlter retardation assay was carried out on striatum samples from
6 month old WT, KIQ175, CK2a0 þ / and KIQ175/CK2a0 þ / mice. Total tissue
protein extract (175 mg protein) was loaded onto a cellulose acetate membrane and
probed for Htt aggregation with Mab2166 (Millipore) and in parallel samples were
loaded onto nitrocellulose membrane to probe for GAPDH as loading control.
Protein expression and puriﬁcation. A DNA cassette encoding a codon-opti-
mized human HSF1 was sub-cloned into the pET15b expression vector containing
an amino-terminal His6 tag using NdeI and XhoI to generate hHSF1-pET15b. The
resulting plasmid was transformed into Escherichia coli strain BL21(DE3). Over-
night cultures were diluted 1:100 and grown to OD600¼ 0.6 at 37 C. Cultures were
transferred to 15 C, induced with 1mM isopropyl 1-thio-b-D-galactopyranoside,
and grown for 16 h. Cell pellets were lysed in nickel-nitrilotriacetic acid buffer (NB:
50mM HEPES, pH 7.5, 300mM NaCl) supplemented with 20mM imidazole HCl
(Im-HCl), using sonication three times with 30-s bursts. Lysates were cleared by
centrifugation at 20,000 g for 30min and incubated with 2ml (bed volume) of
nickel-nitrilotriacetic acid-agarose beads (Qiagen) per liter of culture. Beads were
washed twice with NBþ 40mM Im-HCl, twice with NB supplemented with 40mM
Im-HCl, 5mM ATP, and 20mM MgCl2, and once with NBþ 40mM Im-HCl.
Bound protein was eluted with NBþ 250mM Im-HCl. Eluted proteins were
separated on a Sephacryl S400 (GE Healthcare) gel ﬁltration column using an
A¨KTA FPLC (GE Healthcare) at a ﬂow rate of 1.3ml per min in 25mM HEPES,
pH 7.5, and 150mM NaCl at 4˚C. Fractions corresponding to HSF1 monomer and
HSF1 trimer were collected, pooled, concentrated and aliquoted at 10 mM
(B0.6mgml 1), ﬂash-frozen in N2, and stored at  80 C. GST-CK2a and
GST-CK2a0 expression vectors were purchased from Addgene (pDB1 #27083 and
pDB6 #27084, respectively). Vectors were transformed into E. coli strain BL21
(DE3). Overnight cultures were diluted 1:100, grown to OD600¼ 0.6 at 37 C and
induced with 1mM isopropyl 1-thio-b-D-galactopyranoside for 5 h at 37 C. Cell
pellets were lysed in GST equilibration buffer (50mM Tris, 150mM sodium
chloride, pH 8.0) supplemented, using sonication three times with 30 s bursts.
Lysates were cleared by centrifugation at 20,000g for 30min and incubated with
2ml (bed volume) of Glutathione agarose beads (Pierce) per liter of culture. Beads
were washed twice with equilibration buffer and GST-CK2 subunits eluted with
equilibration buffer (50mM Tris, 150mM sodium chloride, pH 8.0) supplemented
with 10mM reduced Glutathione. Eluted proteins were concentrated using
5,000MWCO centricon, aliquoted (B5mgml 1), ﬂash-frozen in N2 and stored at
 80 C.
In vitro phosphorylation of HSF1 by CK2. Quantiﬁcation of the speciﬁc activity
(U per ml) of GST-CK2a (Addgene pDB1-27083) and GST-CK2a0 (Addgene
pDB6-27084) puriﬁed recombinant enzymes was performed using casein kinase
assay kit (CycLex) and commercial CK2 holoenzyme (New England Biolabs) as
positive control for phosphorylation. Quantiﬁcation was carried out following per
manufacture´s instructions. Puriﬁed recombinant human HSF1 trimer (1 mg) was
incubated with recombinant CK2 (Holoenzyme or GST puriﬁed subunits CK2a or
CK2a0) with 5,000Uml 1. As negative controls for the assay we used samples
without ATP or samples without enzyme. The reaction was carried out at 37 C
during 30min (control conditions) or at 37 C during 20min followed by 10min at
42 C (Heat shock conditions). 6 SDS was added and boiled for 2min to
terminate the reaction. Samples were analysed by phosphoproteomics.
Immunoblot analysis. Protein samples were separated on 4–20% SDS Criterion
TGX Stain-Free gels (BioRad) at 110V. Proteins were transferred to a nitrocellulose
membrane (BioRad 0.2 mm) in Tris–Glycine Buffer (25 nM Tris-Base, 200mM
Glycine) at 25V for 30min in Trans Turbo Transfer system (BioRad). The
membrane was blocked with 5% non-fat dry milk in TBS containing 0.25%
Tween-20 (TBST) for 1 h at room temperature, incubated with primary antibodies
1:1,000 in TBST containing 2.5% milk overnight at 4 C, and then washed 3 times
for 15min each in TBST followed by incubation with secondary Amersham
ECL HRP Conjugated Antibodies 1:5,000 in TBST containing 2.5% milk
(GE Healthcare) for 1 h at room temperature. After washing three times for 15min
each in TBST bands were detected with SuperSignal Chemiluminiscent substrate
(Thermo Scientiﬁc). Primary antibodies used in this study were used at 1:1,000
and are: anti-FLAG (M2, Sigma), anti-HA (Y-11, Santa Cruz), anti-Pgk1 (22C5,
Invitrogen), anti-GAPDH (6C5, Santa Cruz), anti-GFP (Sc8334, Santa Cruz),
rabbit anti-HSF1 (Bethyl42), rat anti-HSF1 (10H8, Enzo), anti-HSF1-S303P
(Ab47369, Abcam), anti-HSF1-S307 (sc135640, Santa Cruz), anti-Hsp70
(C92F3A-5, Enzo), anti-Hsp25 (ADI-SPA-801-F, Enzo), anti-CK2a (Ab6040,
Abcam), anti-CK2a0 (Ab75309, Abcam), anti-CK2b (Ab6025, Abcam),
anti-FBXW7 (Ab109617, Abcam), anti-Htt (Mab2166, Chemicon) and (Mab1574,
Millipore). Anti-Hsp60 (SPA-807, Stressgene), anti-Hsp90 (ADI-SPA-846F, Enzo),
anti-Erdj3 (C-7, Santa Cruz), anti-Hspb5 ab-Crystallin (F-10, Santa Cruz),
anti-Bag3 (ALX-803-323-C100, Enzo Life Sciences), anti-AR (N-20, sc816, Santa
Cruz), anti-panGsk3 (IH8, Santa Cruz).
C. elegans experiments. All Caenorhabditis elegans strains were maintained on
normal growth media seeded with E. coli OP50 until required for experiments.
To perform RNAi against kin-3, E. coli HT115 expressing kin-3 double-stranded
RNA or the vector L4440 (control) was cultured in LB broth containing ampicillin
(50 mgml 1) for 8 h. Cultures were concentrated (10 ) and seeded onto normal
growth media plates containing isopropyl-1-thio-b-D-galactopyranoside (3mM)
and ampicillin (50 mgml 1). Plates were incubated overnight at 37 C and allowed
to cool before plating animals. For each strain, Q37::YFP (rmIs225[Punc-54::q37::
yfp]II) and Q37::YFP;hsf-1(sy441) (from Dr. Morimoto, Northwestern University),
L4s were plated on RNAi plates and grown for a total of 5 days at 20 C. To prevent
progeny from contaminating plates, animals were transferred every two days.
Phosphoproteomic analysis. Phosphoproteomic analysis was performed by the
Proteomics and Metabolomics Shared Resource at Duke University. Protein
samples were mixed with loading buffer and reduced with 10mM DTT at 70 C
for 10min before SDS–PAGE separation on a 4–12% bis-tris acrylamide gel
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(NuPAGE, Invitrogen) with colloidal coomassie staining. Bands corresponding
to HSF1 were excised and subjected to standardized in-gel trypsin digestion
(http://www.genome.duke.edu/cores/proteomics/sample-preparation/documents/
In-gelDigestionProtocolrevised.pdf). Extracted peptides were lyophilized to dryness
and resuspended in 12ml of 0.2% formic acid/2% acetonitrile. Phosphopeptides
were enriched using GL Biosciences p10 TiO2-derivatized tips according to the
manufacturer’s protocol. Each sample was subjected to chromatographic separa-
tion on a Waters NanoAquity UPLC equipped with a 1.7 mm BEH130 C18 75 mm
I.D. X 250mm reversed-phase column. The mobile phase consisted of (A) 0.1%
formic acid in water and (B) 0.1% formic acid in acetonitrile. Following a 4ml
injection, peptides were trapped for 3min on a 5mm Symmetry C18 180 mm I.D.
X 20mm column at 5 ml per min in 99.9% A. The analytical column was then
switched in-line and a linear elution gradient of 5% B to 40% B was performed over
30min at 400 nl per min. The analytical column was connected to a fused silica
PicoTip emitter (New Objective, Cambridge, MA) with a 10mm tip oriﬁce and
coupled to a QExactive Plus mass spectrometer through an electrospray interface
operating in a data-dependent mode of acquisition. The instrument was set to
acquire a precursor MS scan from m/z 375–1675 with MS/MS spectra acquired for
the ten most abundant precursor ions. For all experiments higher-energy collisional
dissociation (HCD) energy settings were 27v and a 120 s dynamic exclusion was
employed for previously fragmented precursor ions.
Raw LC-MS/MS data ﬁles were processed in Proteome Discoverer (Thermo
Scientiﬁc) and then submitted to independent Mascot searches (Matrix Science)
against a SwissProt database (Human taxonomy) containing both forward and
reverse entries of each protein (20,322 forward entries). Search tolerances were
5 p.p.m. for precursor ions and 0.02Da for product ions using trypsin speciﬁcity
with up to two missed cleavages. Carbamidomethylation (þ 57.0214Da on C) was
set as a ﬁxed modiﬁcation, whereas oxidation (þ 15.9949Da on M), deamidation
(þ 0.98Da on NQ), and phosphorylation (þ 79.99Da on STY) were considered
dynamic mass modiﬁcations. All searched spectra were imported into Scaffold
(v4.3, Proteome Software) and scoring thresholds were set to achieve a peptide false
discovery rate of 1% using the PeptideProphet algorithm. Raw data can be found in
Supplementary Data 1 and 2.
Statistical analysis. The t-test was used to compare mean values in groups of
samples for all experiments. Error bars were calculated using mean±s.e.m. with a
group size nZ3. All reported P-values were calculated for groups with unequal
variance using the Excel software programme (Microsoft) and a two-tailed
unpaired t-test. Statistical signiﬁcance of CK2 subunits mRNA expression between
control groups and HD patients group (n¼ 7) was analysed by a one-tailed
unpaired t-test. Reported P-values for all experiments correspond to *Po0.05,
**Po0.01, ***Po0.001; NS, not signiﬁcant.
Data availability. All data generated or analysed during this study are included in
this published article (and its Supplementary Information ﬁles).
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